News | Heart Valve Technology | August 09, 2017

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System

First trial of its kind to evaluate minimally invasive treatment using clip technology for moderate or severe tricuspid regurgitation

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System

August 9, 2017 — Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-based repair system for treating people with moderate or severe tricuspid regurgitation (TR). The first patient was enrolled at Abbott Northwestern Hospital by Paul Sorajja, M.D., cardiologist at Minneapolis Heart Institute and Abbott Northwestern Hospital.

The transcatheter tricuspid valve repair (TTVR) system builds upon Abbott's MitraClip System, which has shown to predictably and effectively treat mitral regurgitation, a similar disease impacting the left side of the heart.

Tricuspid regurgitation is a condition in which the valve between the heart's two chambers on the right side does not close properly, resulting in a backward flow of blood into the right atrium. The consequences of leaving it untreated can be substantial – people often develop other conditions such as atrial fibrillation, heart failure and, ultimately, death. Currently, there are no approved minimally invasive treatments for people with moderate or severe tricuspid regurgitation.

"Current pharmacological and surgical treatment options are not meeting the needs of people living with tricuspid regurgitation," said Georg Nickenig, M.D., Ph.D., professor and chief, Department of Cardiology, University Hospital, Bonn, Germany, and lead investigator of the study. "Abbott's MitraClip has shown positive results for mitral regurgitation, and we hope this study shows that a similar clip-based technology may effectively treat people with tricuspid regurgitation."

The clinical trial is expected to support Abbott's application for CE Mark in Europe for a clip-based transcatheter tricuspid valve repair system.

The study, called TRILUMINATE, is a prospective, single-arm, multi-center study designed to evaluate the performance of clip-based technology in approximately 75 symptomatic patients at 25 sites across the United States and Europe. The primary endpoints are an echocardiographic tricuspid regurgitation reduction of ≥ 1 grade at 30 days post-procedure, and the assessment of major adverse events at six months.

Read the article "Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial."

Watch the VIDEO "Transcatheter Tricuspid Valve Repair and Replacement Technologies," an interview with Rebecca Hahn, M.D., FASE, at ASE 2017.

For more information: www.mitraclip.com


Related Content

News | Cardiovascular Clinical Studies

October 14, 2022 — Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid ...

Home October 14, 2022
Home
News | Cardiovascular Clinical Studies

October 11, 2022 — The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass ...

Home October 11, 2022
Home
News | Cardiovascular Clinical Studies

October 4, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase ...

Home October 04, 2022
Home
News | Cardiovascular Clinical Studies

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
Subscribe Now